Table 1.
Current clinical trials evaluating the efficacy and safety of dupilumab in various disease states.
| Study Title | Phase | Condition | Intervention | Study Population | Status | Patient Number |
Identifier |
|---|---|---|---|---|---|---|---|
| Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | 3 | Atopic dermatitis |
Dupilumab | Pediatrics (≥ 6 months to < 18 years) | Enrolling by invitation | 765 | NCT02612454 |
| Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis | 3 | Atopic dermatitis |
Dupilumab Placebo |
Adolescents (≥ 6 months to < 6 years) | Completed | 251 | NCT03054428 |
| Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) | 3 | Asthma | Dupilumab Asthma controllers |
Pediatrics (7 to 12 years) | Recruiting | 377 | NCT03560466 |
| Evaluation of Dupilumab in Children With Uncontrolled Asthma (VOYAGE) | 3 | Asthma | Dupilumab Placebo |
Pediatrics (6 to 11 years) | Recruiting | 471 | NCT02948959 |
| Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | 3 | Eosinophilic esophagitis | Dupilumab Placebo |
Adults and adolescents (12 years and older) | Recruiting | 425 | NCT03633617 |
| An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis | 3 | Nasal polyps |
Dupilumab Placebo |
Adults | Completed | 60 | NCT01920893 |
| A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-24) | 3 | Nasal polyps |
Dupilumab Placebo |
Adults | Completed | 276 | NCT02912468 |
| A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema) | 2 | Atopic dermatitis |
Dupilumab | Adolescents (≥ 6 to <18 years) | Completed | 78 | NCT02407756 |
| Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | 2 | Atopic dermatitis |
Dupilumab Placebo |
Pediatrics (≥ 6 months to < 6 years) | Recruiting | 280 | NCT03346434 |
| DEGS – Dupilumab for Eosinophilic Gastritis Study | 2 | Eosinophilic gastritis | Dupilumab Placebo |
Adults | Not yet recruiting | 109 | NCT01548404 |
| Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) | 2 | Alopecia areata |
Dupilumab Placebo |
Adults | Recruiting | 54 | NCT03359356 |
| Dupilumab in Chronic Spontaneous Urticaria | 2 | Chronic urticaria/ Recurrent angioedema |
Dupilumab Placebo |
Adults | Recruiting | 72 | NCT03749135 |
| Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) | 2 | Eosinophilic esophagitis | Dupilumab Placebo |
Adult | Completed | 47 | NCT02379052 |